美中期选举后生物医药行业展望
Post-Hoc Live: What the US midterm elections mean for biopharma
美国民主党似乎赢得国会控制权,可能引发对特朗普政府“最惠国”协议的审查、HHS部长Kennedy Jr.的调查以及FDA政策变动等。生物医药行业需应对更严格的监管环境和政策不确定性。
Democrats appear to have won control of Congress in a wave election, and the results could have wide-ranging implications for biotech and pharma. It likely means scrutiny of the Trump administration’s “most favored nation” deals, investigations into HHS Secretary Robert F. Kennedy Jr., shifts in China policy, changes to funding rules for US research, plus more policy and people turbulence at the FDA. Endpoints News Senior Reporter Max Bayer and I were joined by frequent Post-Hoc Live guest Nick Shipley, an expert on biopharma policy and politics. We broke down what the midterm results mean for biopharma and how the industry will navigate Washington over the next few years. https://youtube.com/live/ghjQxZj1bWQ?feature=share Watch our conversation on YouTube. — Drew Armstrong, Executive Editor
来源:Endpoints News 生物医药 · endpoints.news